Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2001-08-23
2008-07-15
Nashed, Nashaat T. (Department: 1656)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S423000, C424S435000, C424S484000, C435S069100, C435S069700, C435S226000, C435S252300, C435S320100
Reexamination Certificate
active
07399466
ABSTRACT:
The object of the present invention is to increase PHEX activity to improve the osteogenic process in a mammal where this process has been diminished due to pathology or a condition that require osteogenesis. Osteocalcin is an endogenous inhibitor of the PHEX activity. Therefore, the identification of a substance capable of potentiating PHEX activity by preventing the inhibitory action of endogenous inhibitors will improve osteogenesis. Since PHEX is generally associated with the growth plane of bone or teeth and the absence of osteocalcin is associated with increased bone mass, potentiation of PHEX activity can promote bone growth. Increased PHEX activity can also be obtained by administration of the enzyme itself.
REFERENCES:
patent: 5208219 (1993-05-01), Ogawa et al.
patent: 5413989 (1995-05-01), Ogawa et al.
patent: 6787644 (2004-09-01), Cerretti
patent: 6790649 (2004-09-01), Crine et al.
patent: 6881404 (2005-04-01), Boodhoo et al.
patent: 40 08 546 (1990-09-01), None
patent: 0 504 423 (1992-09-01), None
patent: 0 834 740 (1998-04-01), None
patent: 98 10078 (1998-03-01), None
patent: 00 50580 (2000-08-01), None
A. Faimey et al.; “Abnormal ostecalcin binding in rheumatoid arthritis,” 1990; Animals of the Rheumatic Diseases; vol. 49, pp. 229-230.
Guy Boileau et al, “Characterization of PHEX endopeptidase catalytic activity: Identification of parathyroid-hormone-related peptide107-139 as a susbstrate and osteocalcin, PPi and phosphate as inhibitors.”Biochemical Journal, vol. 355, No. 3, May 1, 2001, pp. 707-713.
Yves Sabbagh et al.: “Disease-causing missense mutations in the PHEX gene interfere with membrance targeting of the recombinant protein”Human Molecular Genetics, vol. 10, No. 15, 2001, pp. 1539-1546.
Galia Ghaddar et al., “Molecular cloning and biochemical characterization of a new mouse testis soluble-zinc-metallopeptidase of the neprilysin family”,Biochemical Journal, vol. 347, No. 2, Apr. 15, 2000, pp. 419-429.
Laurent Beck et al., “Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked Hypophosphatemic mice.”Journal of Clinical Investigation, vol. 99, No. 6, 1997, pp. 1200-1209.
P.S.N. Rowe, “The Role Of The Phex Gene (PEX) In Families With X-Linked Hypophosphataemic Rickets”Current Opinion In Nephrology and Hypertension, Rapid Science, vol. 7, No. 4, 1998, pp. 367-376.
Kiyono, et al., Partial Translation of Research Report, Abstract only, one page.
DLA Piper (US) LLP
Enobia Pharma Inc.
Moore William W.
Nashed Nashaat T.
LandOfFree
Method and compositions for promoting osteogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for promoting osteogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for promoting osteogenesis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3966368